ZA200305609B - Novel-alkyl-phenylimino-imidazolidine derivatives for treating urinary incontinence. - Google Patents
Novel-alkyl-phenylimino-imidazolidine derivatives for treating urinary incontinence. Download PDFInfo
- Publication number
- ZA200305609B ZA200305609B ZA200305609A ZA200305609A ZA200305609B ZA 200305609 B ZA200305609 B ZA 200305609B ZA 200305609 A ZA200305609 A ZA 200305609A ZA 200305609 A ZA200305609 A ZA 200305609A ZA 200305609 B ZA200305609 B ZA 200305609B
- Authority
- ZA
- South Africa
- Prior art keywords
- phen
- compound
- tert
- iminoimidazolidine
- acceptable salt
- Prior art date
Links
- 206010046543 Urinary incontinence Diseases 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims description 56
- 229910052794 bromium Inorganic materials 0.000 claims description 20
- 229910052801 chlorine Inorganic materials 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000026533 urinary bladder disease Diseases 0.000 claims 2
- DISXFZWKRTZTRI-UHFFFAOYSA-N 4,5-dihydro-1h-imidazol-2-amine Chemical compound NC1=NCCN1 DISXFZWKRTZTRI-UHFFFAOYSA-N 0.000 claims 1
- MSYFITFSZJKRQJ-UHFFFAOYSA-N 4,5-dihydroimidazol-1-amine Chemical compound NN1CCN=C1 MSYFITFSZJKRQJ-UHFFFAOYSA-N 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 37
- 239000000460 chlorine Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 9
- 206010021639 Incontinence Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- -1 imido Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000022170 stress incontinence Diseases 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 210000003903 pelvic floor Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RABBMOYULJIAFU-UHFFFAOYSA-N 1h-pyrrole;thiophene Chemical class C=1C=CNC=1.C=1C=CSC=1 RABBMOYULJIAFU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YYPQPWYCPPSSGY-UHFFFAOYSA-N 4-(1H-pyrazol-5-yl)imidazol-2-imine Chemical class N1N=C(C=C1)C1=NC(N=C1)=N YYPQPWYCPPSSGY-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JCOPITWIWLFFPC-UHFFFAOYSA-N n-phenyl-4,5-dihydro-1h-imidazol-2-amine Chemical class N1CCN=C1NC1=CC=CC=C1 JCOPITWIWLFFPC-UHFFFAOYSA-N 0.000 description 1
- YEPNQNIIERDOCM-UHFFFAOYSA-N n-phenylimidazol-2-imine Chemical class N1=CC=NC1=NC1=CC=CC=C1 YEPNQNIIERDOCM-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10106214A DE10106214A1 (de) | 2001-02-10 | 2001-02-10 | Neue Alkyl-phenylimino-imidazolidin-Derivate zur Behandlung der Harninkontinenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200305609B true ZA200305609B (en) | 2004-04-29 |
Family
ID=7673601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200305609A ZA200305609B (en) | 2001-02-10 | 2003-07-21 | Novel-alkyl-phenylimino-imidazolidine derivatives for treating urinary incontinence. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1362038A1 (hu) |
| JP (1) | JP2004517963A (hu) |
| KR (1) | KR20030076653A (hu) |
| CN (1) | CN1491216A (hu) |
| AR (1) | AR035226A1 (hu) |
| BG (1) | BG108036A (hu) |
| BR (1) | BR0206949A (hu) |
| CA (1) | CA2437809A1 (hu) |
| CZ (1) | CZ20032146A3 (hu) |
| DE (1) | DE10106214A1 (hu) |
| EA (1) | EA200300835A1 (hu) |
| EC (1) | ECSP034700A (hu) |
| EE (1) | EE200300379A (hu) |
| HU (1) | HUP0303004A3 (hu) |
| IL (1) | IL157297A0 (hu) |
| MX (1) | MXPA03007127A (hu) |
| NO (1) | NO20033368D0 (hu) |
| PL (1) | PL362149A1 (hu) |
| SK (1) | SK10132003A3 (hu) |
| WO (1) | WO2002064570A1 (hu) |
| ZA (1) | ZA200305609B (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100378097C (zh) * | 2003-05-09 | 2008-04-02 | 弗·哈夫曼-拉罗切有限公司 | 作为α-1肾上腺素能激动剂的甲基吲哚和甲基吡咯并吡啶 |
| JP4168086B1 (ja) * | 2008-04-16 | 2008-10-22 | 国立大学法人福井大学 | イミダゾリン誘導体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3202660A (en) * | 1961-10-09 | 1965-08-24 | Boehringer Sohn Ingelheim | Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes |
| HU192986B (en) * | 1984-05-23 | 1987-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for production of imidasodiline derivatives |
| DE19514579A1 (de) * | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| FR2761061B1 (fr) * | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de benzenesulfonamide, leur preparation et leur application en therapeutique |
| SG72827A1 (en) * | 1997-06-23 | 2000-05-23 | Hoffmann La Roche | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives |
-
2001
- 2001-02-10 DE DE10106214A patent/DE10106214A1/de not_active Withdrawn
-
2002
- 2002-01-22 EP EP02704665A patent/EP1362038A1/de not_active Withdrawn
- 2002-01-22 MX MXPA03007127A patent/MXPA03007127A/es unknown
- 2002-01-22 KR KR10-2003-7010280A patent/KR20030076653A/ko not_active Application Discontinuation
- 2002-01-22 CZ CZ20032146A patent/CZ20032146A3/cs unknown
- 2002-01-22 JP JP2002564503A patent/JP2004517963A/ja active Pending
- 2002-01-22 BR BR0206949-0A patent/BR0206949A/pt active Pending
- 2002-01-22 PL PL36214902A patent/PL362149A1/xx not_active Application Discontinuation
- 2002-01-22 EE EEP200300379A patent/EE200300379A/xx unknown
- 2002-01-22 IL IL15729702A patent/IL157297A0/xx unknown
- 2002-01-22 CN CNA02804570XA patent/CN1491216A/zh active Pending
- 2002-01-22 CA CA002437809A patent/CA2437809A1/en not_active Abandoned
- 2002-01-22 HU HU0303004A patent/HUP0303004A3/hu unknown
- 2002-01-22 EA EA200300835A patent/EA200300835A1/ru unknown
- 2002-01-22 WO PCT/EP2002/000576 patent/WO2002064570A1/de not_active Application Discontinuation
- 2002-01-22 SK SK1013-2003A patent/SK10132003A3/sk unknown
- 2002-02-08 AR ARP020100417A patent/AR035226A1/es not_active Withdrawn
-
2003
- 2003-07-21 ZA ZA200305609A patent/ZA200305609B/en unknown
- 2003-07-22 EC EC2003004700A patent/ECSP034700A/es unknown
- 2003-07-28 NO NO20033368A patent/NO20033368D0/no not_active Application Discontinuation
- 2003-07-28 BG BG108036A patent/BG108036A/bg active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2437809A1 (en) | 2002-08-22 |
| WO2002064570A1 (de) | 2002-08-22 |
| EP1362038A1 (de) | 2003-11-19 |
| SK10132003A3 (sk) | 2004-02-03 |
| AR035226A1 (es) | 2004-05-05 |
| MXPA03007127A (es) | 2003-11-18 |
| HUP0303004A3 (en) | 2004-07-28 |
| CN1491216A (zh) | 2004-04-21 |
| BG108036A (bg) | 2004-12-30 |
| NO20033368L (no) | 2003-07-28 |
| NO20033368D0 (no) | 2003-07-28 |
| EE200300379A (et) | 2003-12-15 |
| EA200300835A1 (ru) | 2004-02-26 |
| KR20030076653A (ko) | 2003-09-26 |
| DE10106214A1 (de) | 2002-08-14 |
| JP2004517963A (ja) | 2004-06-17 |
| HUP0303004A2 (hu) | 2003-12-29 |
| ECSP034700A (es) | 2003-08-29 |
| CZ20032146A3 (cs) | 2003-12-17 |
| BR0206949A (pt) | 2004-02-25 |
| IL157297A0 (en) | 2004-02-19 |
| PL362149A1 (en) | 2004-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6310103B1 (en) | S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders | |
| JP2001525359A (ja) | アミノチオール化合物を用いた、神経及び腎障害ならびに治療に伴う毒性の治療方法 | |
| KR20010040925A (ko) | 메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도 | |
| US8772278B2 (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| SK287972B6 (sk) | Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof | |
| US5021410A (en) | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | |
| US5290781A (en) | Ketaneserinol as an agent to reduce intraocular pressure | |
| JP2011256195A (ja) | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト | |
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| ZA200305609B (en) | Novel-alkyl-phenylimino-imidazolidine derivatives for treating urinary incontinence. | |
| EP1466598A2 (en) | PDE-IV inhibitors | |
| SK287420B6 (sk) | Použitie zlúčenín 1-fenyl-3-dimetylamino-propánu na výrobu liečiva na terapiu inkontinencie moču | |
| KR100310665B1 (ko) | 피부질환치료용약제학적조성물 | |
| IE50091B1 (en) | Antimycotic vaginal tablets with increased bioavailability of the active compounds | |
| EP0443028B1 (en) | Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer | |
| US6060480A (en) | Preventives/remedies for muscle tissue degenerations | |
| SK287536B6 (sk) | Použitie substituovaných zlúčenín 6-dimetylaminometyl-1-fenyl- cyklohexanónu na terapiu inkontinencie moču | |
| CN107007608B (zh) | I型和ii型糖尿病的治疗 | |
| SK287701B6 (sk) | Použitie zlúčenín 6-dimetylaminometyl-1-fenyl-cyklohexánu na výrobu liečiva | |
| JP2005515984A (ja) | メトホルミンと４−オキソブタン酸の組合せを有する薬剤組成物、および糖尿病治療へのその適用 | |
| CN103037861A (zh) | 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途 | |
| KR101052804B1 (ko) | 과활동방광을 치료하기 위한 페녹시아세트산 유도체의 사용 | |
| US20020169193A1 (en) | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | |
| US4148906A (en) | Growth hormone inhibitors | |
| TW404937B (en) | 2-Chloro-5-trifluoromethyl-benzoylguanidines having an action of inhibiting cellular Na<+>/H<+> exchange mechanism, process for their preparation, and their pharmaceutical compositions |